{"id":6578,"date":"2023-04-18T06:55:45","date_gmt":"2023-04-18T13:55:45","guid":{"rendered":"https:\/\/allocare.caredx.com\/?p=6578"},"modified":"2023-04-18T06:55:53","modified_gmt":"2023-04-18T13:55:53","slug":"fda-oks-cell-therapy-to-lower-infection-risk-after-stem-cell-transplant","status":"publish","type":"post","link":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2023\/04\/18\/fda-oks-cell-therapy-to-lower-infection-risk-after-stem-cell-transplant\/","title":{"rendered":"FDA OKs Cell Therapy to Lower Infection Risk After Stem Cell Transplant"},"content":{"rendered":"<span class=\"simplefavorite-button has-count loading\" data-postid=\"6578\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"1\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>\n<h2 class=\"wp-block-heading\"><em>\u2014 Omidubicel reduced infections in blood cancer patients from 60% to 39% at 100 days posttransplant<\/em><\/h2>\n\n\n\n<p>By Ian Ingram<\/p>\n\n\n\n<p>The FDA\u00a0<a rel=\"noreferrer noopener\" href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell\" target=\"_blank\">approved omidubicel (Omisirge) opens in a new tab or window<\/a>\u00a0to reduce the risk for infections in hematologic cancer patients undergoing stem cell transplant, the agency announced on Monday.<\/p>\n\n\n\n<p>Omidubicel is designed to speed up neutrophil recovery and is indicated for patients ages 12 and up planning to undergo umbilical cord blood transplantation (UCBT) following a myeloablative conditioning regimen, which can impair the immune system. <a href=\"https:\/\/www.medpagetoday.com\/transplantation\/transplantation\/104063\">Read more<\/a> in MedPage Today.<\/p>\n<span class=\"simplefavorite-button has-count loading\" data-postid=\"6578\" data-siteid=\"1\" data-groupid=\"1\" data-favoritecount=\"1\" style=\"\">Loading<span class=\"sf-icon-spinner-wrapper\"><i class=\"sf-icon-spinner\"><\/i><\/span><\/span>","protected":false},"excerpt":{"rendered":"<p>Loading \u2014 Omidubicel reduced infections in blood cancer patients from 60% to 39% at 100 days posttransplant By Ian Ingram The FDA\u00a0approved omidubicel (Omisirge) opens in a new tab or &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/indexphp\/post\/2023\/04\/18\/fda-oks-cell-therapy-to-lower-infection-risk-after-stem-cell-transplant\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;FDA OKs Cell Therapy to Lower Infection Risk After Stem Cell Transplant&#8221;<\/span><\/a><\/p>\n","protected":false},"author":208,"featured_media":3835,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_EventAllDay":false,"_EventTimezone":"","_EventStartDate":"","_EventEndDate":"","_EventStartDateUTC":"","_EventEndDateUTC":"","_EventShowMap":false,"_EventShowMapLink":false,"_EventURL":"","_EventCost":"","_EventCostDescription":"","_EventCurrencySymbol":"","_EventCurrencyCode":"","_EventCurrencyPosition":"","_EventDateTimeSeparator":"","_EventTimeRangeSeparator":"","_EventOrganizerID":[],"_EventVenueID":0,"_OrganizerEmail":"","_OrganizerPhone":"","_OrganizerWebsite":"","_VenueAddress":"","_VenueCity":"","_VenueCountry":"","_VenueProvince":"","_VenueZip":"","_VenuePhone":"","_VenueURL":"","_VenueStateProvince":"","_VenueLat":"","_VenueLng":"","_tribe_blocks_recurrence_rules":"","_tribe_blocks_recurrence_description":"","_tribe_blocks_recurrence_exclusions":"","_ecp_custom_2":"","footnotes":""},"categories":[45,244],"tags":[1859,1858,245],"post_format":[],"Dislikes":"","Likes":"","simplefavorites_count":"1","views":"1250","post_likes_plusCounter":"3","post_dislikes_plusCounter":"","acf":[],"_links":{"self":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/6578"}],"collection":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/users\/208"}],"replies":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/comments?post=6578"}],"version-history":[{"count":1,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/6578\/revisions"}],"predecessor-version":[{"id":6579,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/posts\/6578\/revisions\/6579"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media\/3835"}],"wp:attachment":[{"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/media?parent=6578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/categories?post=6578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/tags?post=6578"},{"taxonomy":"post_format","embeddable":true,"href":"https:\/\/app-allocare-wordpress-linux-prod.azurewebsites.net\/index.php\/wp-json\/wp\/v2\/post_format?post=6578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}